Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LyRICX: Liposomal irinotecan, carboplatin or oxaliplatin in first-line treatment of esophagogastric cancer
2018-002767-26Phase 2Active
- Sponsor
- Academic Medical Center
- Start
- Sep 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of irinotecan, carboplatin and oxaliplatin in esophagogastric junction cancer (3 arms), sponsored by Academic Medical Center. Primary endpoints: Progression-free survival (PFS1) and Neurotoxicity. Started Sep 2018; status: active.
02
Drugs
irinotecancarboplatinoxaliplatin
03
Conditions
esophagogastric junction cancer
Beyond the preview
Go deeper on 2018-002767-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002767-26.